# MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

> **NCT04579666** · PHASE2 · TERMINATED · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 249 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease

## Interventions

- **DRUG:** Pegcetacoplan (APL-2)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04579666
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-30
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-07-13
- **Target enrollment:** 249 (ACTUAL)
- **Why stopped:** The study did not meet primary endpoint at Week 52. The study also did not meet key secondary efficacy endpoints. Pegcetacoplan (APL-2) was well tolerated in the study, and the data were consistent with the established safety profile.
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04579666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04579666, "MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04579666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*